GCM
CLVS

Gruss Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Gruss Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-150,000
Closed -$2.88M – 46
2016
Q1 		$2.88M Buy
+150,000
New +$3.17M 0.09% 36

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Gruss Capital Management's CLVS Position: Q2 2016 in Review

Gruss Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q2 2016, closing a stake of 150,000 shares — an estimated $2.88M sold.

Gruss Capital Management first reported a position in CLVS in Q1 2016 and held it in 1 quarter. The position peaked at $2.88M in Q1 2016. 122 funds tracked by Wall St. Rank hold CLVS as of Q2 2016.

  • Gruss Capital Management reported no remaining Clovis Oncology, Inc. position as of Q2 2016 after selling out during the quarter.
  • Gruss Capital Management sold 150,000 Clovis Oncology, Inc. shares in Q2 2016, an estimated $2.88M.
  • Gruss Capital Management first reported a position in Clovis Oncology, Inc. in Q1 2016 and held it in 1 quarter.
  • Gruss Capital Management's Clovis Oncology, Inc. position peaked at $2.88M in Q1 2016.
  • 122 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2016.

Based on Gruss Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.